Sustained release aminopyridine composition

US8551523B2 · kind B2 · utility

Assignee

• Acorda Therapeutics, Inc. · US

Inventors

• Andrew R. Blight · Pontefract, GB
• Ron Cohen · Ramat HaSharon, IL

Key dates

• Filing date: Jul 20, 2011
• Grant date: Oct 8, 2013
• Expiry date: Sep 30, 2031

Classification

• Technology area (CPC —): General

Abstract

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.